Human Reproduction, Vol. 11, No. 10, pp. 2114-2118, 1996
© 1996 European Society of Human Reproduction and Embryology
research-article |
EndocrinologyHormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix)
1Centre for Reproductive Medicine, University Hospital and Medical School, Dutch-speaking Brussels Free University Laarbeeklaan 101, 1090 Brussels, Belgium 2ASTA Medica AG Frankfurt Main, Germany 33Department of Obstetrics and Gynecology of the Medical University of Lübeck Germany
Correspondence: 4To whom correspondence should be addressed
A third-generation gonadotrophin-releasing hormone antagonist (Cetrorelix) was used during ovarian stimulation in 32 patients undergoing assisted reproduction, in order to prevent the premature luteinizing hormone (LH) surge. In all patients, ovarian stimulation was carried out with two or three ampoules of human menopausal gonadotrophin (HMG), starting on day 2 of the menstrual cycle. In addition, 0.5 mg of Cetrorelix was administered daily from day 6 of HMG treatment until the day of ovulation induction by human chorionic gonadotrophin (HCG). A significant drop in plasma LH concentration was observed within a few hours of the first administration of Cetrorelix (P<0.005). Moreover, no LH surge was detected at any point in the treatment period in any of the 32 patients. A mean oestradiol concentration of 2122±935 ng/1 was observed on the day of the HCG administration, indicating normal folliculogenesis. Like LH, progesterone concentration also dropped within a few hours of the first administration of Cetrorelix (P< 0.005). A 0.5 mg daily dose of Cetrorelix prevented a premature LH surge in all the 32 patients treated.
Key words: GnRH antagonist (Cetrorelix)/in-vitro fertilization/LH surge/ovarian stimulation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H.M. Fatemi, B. Popovic-Todorovic, E. Papanikolaou, P. Donoso, and P. Devroey An update of luteal phase support in stimulated IVF cycles Hum. Reprod. Update, November 1, 2007; 13(6): 581 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Prapas, Y. Prapas, Y. Panagiotidis, S. Prapa, P. Vanderzwalmen, R. Schoysman, and G. Makedos GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study Hum. Reprod., June 1, 2005; 20(6): 1516 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Kolibianakis, C. Albano, M. Camus, H. Tournaye, A. C. Van Steirteghem, and P. Devroey Initiation of Gonadotropin-Releasing Hormone Antagonist on Day 1 as Compared to Day 6 of Stimulation: Effect on Hormonal Levels and Follicular Development in in Vitro Fertilization Cycles J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5632 - 5637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Wely, N. Bayram, and F. van der Veen Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review based on a Cochrane review Hum. Reprod., June 1, 2003; 18(6): 1143 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.J. Thong, P.Y. Yong, and Q. Menezes The administration of the GnRH antagonist, cetrorelix, to ooctye donors simplifies oocyte donation Hum. Reprod., June 1, 2003; 18(6): 1256 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bonduelle, I. Liebaers, V. Deketelaere, M.-P. Derde, M. Camus, P. Devroey, and A. Van Steirteghem Neonatal data on a cohort of 2889 infants born after ICSI (1991-1999) and of 2995 infants born after IVF (1983-1999) Hum. Reprod., March 1, 2002; 17(3): 671 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Garcia-Velasco, V. Isaza, C. Vidal, A. Landazabal, J. Remohi, C. Simon, and A. Pellicer Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix) Hum. Reprod., December 1, 2001; 16(12): 2533 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ragni, W. Vegetti, E. Baroni, M. Colombo, M. Arnoldi, G. Lombroso, and P. G. Crosignani Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist Hum. Reprod., November 1, 2001; 16(11): 2258 - 2262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wikland, C. Bergh, K. Borg, T. Hillensjo, C.M. Howles, A. Knutsson, L. Nilsson, and M. Wood A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI Hum. Reprod., August 1, 2001; 16(8): 1676 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tavaniotou, C. Albano, J. Smitz, and P. Devroey Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix Hum. Reprod., April 1, 2001; 16(4): 663 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Albano, R.E. Felberbaum, J. Smitz, H. Riethmuller-Winzen, J. Engel, K. Diedrich, and P. Devroey Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin Hum. Reprod., March 1, 2000; 15(3): 526 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Out, D. D.M. Braat, B. M.E. Lintsen, T. Gurgan, O. Bukulmez, O. Gokmen, G. Keles, P. Caballero, J. M. Gonzalez, F. Fabregues, et al. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon(R)) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation Hum. Reprod., January 1, 2000; 15(1): 29 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Anderson, D. Kinniburgh, and D. T. Baird Preliminary experience of the use of a gonadotrophin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treatment: Case Report Hum. Reprod., October 1, 1999; 14(10): 2665 - 2668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kol, A. Lightman, T. Hillensjo, P. Devroey, B. Fauser, B. Tarlatzis, B. Mannaerts, and J. Itskovitz-Eldor High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze–thaw cycles Hum. Reprod., September 1, 1999; 14(9): 2242 - 2244. [Abstract] [Full Text] [PDF]
|
|